NanoViricides, Inc. (NYSE American: NNVC) has entered into a securities purchase agreement with a single healthcare institutional investor to raise approximately $6 million in gross proceeds through a registered direct offering. The company will issue 3,571,429 shares of common stock (or equivalents) at $1.68 per share. In a concurrent private placement, NanoViricides will issue Series A and Series B warrants to purchase up to 3,571,429 shares each, with exercise prices of $1.75 and $2.00 per share, respectively. The Series A warrants become exercisable six months after issuance and expire in two years, while Series B warrants become exercisable after six months and expire in 5.5 years. The offering is expected to close on or about Nov. 12, 2025, subject to customary conditions. A.G.P./Alliance Global Partners is acting as sole placement agent. Proceeds will be used for working capital and general corporate purposes.
This capital infusion comes at a critical time for NanoViricides, a clinical-stage company developing broad-spectrum antiviral nanomedicines. The company's lead drug candidate, NV-387, is a broad-spectrum antiviral designed to treat respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as mpox/smallpox infections. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials. Another advanced candidate is NV-HHV-1 for the treatment of shingles. The company also has a pipeline targeting viruses such as herpes, HIV, hepatitis C, rabies, dengue, and Ebola.
The financing provides NanoViricides with additional runway to progress its clinical programs. The company's technology is based on the TheraCour nanomedicine platform, which it licenses from TheraCour Pharma, Inc. NanoViricides holds exclusive, perpetual licenses for several antiviral drug candidates. The company's business model relies on licensing technology from TheraCour for specific viral indications, a strategy established since its founding in 2005.
Investors should note that drug development is inherently risky and capital-intensive. NanoViricides acknowledges that the path to typical drug development is extremely lengthy and requires substantial capital. There is no assurance that any of the company's pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development or result in a successful commercial product. For more information, see the full press release here and the company's newsroom here.
